Sjoerd Rodenhuis - Concepedia

Author

Sjoerd Rodenhuis

Also Known As

Aletta Lems, Berry, Donald A., Jelle Wesseling, Rodenhuis S, Rodenhuis S., Rodenhuis, Sjoerd, S RODENHUIS, S Rodenhuis, S. Rodenhuis, Sjoerd Rodenhuis

343

Publications

23.4K

Citations

H-Index

122

Concepts

All Affiliations

The Netherlands Cancer Institute Slotervaartziekenhuis Utrecht University Oncode Institute University Medical Center Utrecht

About

Sjoerd Rodenhuis is an author at The Netherlands Cancer Institute specializing in medicine, oncology, and pathology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	43	86	6.3K
2	Health Sciences	12	12	1.1K
3	Engineering	4	4	361
4	Public Health	2	2	112
5	Natural Sciences	1	1	51

Sjoerd Rodenhuis

171

Publications

21.4K

Citations

H-Index

Page 1

	Year	Citations
A Gene-Expression Signature as a Predictor of Survival in Breast Cancer Marc J. van de Vijver, Yudong D. He, Laura van ‘t Veer, New England Journal of Medicine	2002	6.5K
K-<i>ras</i>Oncogene Activation as a Prognostic Marker in Adenocarcinoma of the Lung Robert J.C. Slebos, R.E. Kibbelaar, Otilia Dalesio, New England Journal of Medicine	1990	809
Impairment of Cognitive Function in Women Receiving Adjuvant Treatment for High-Risk Breast Cancer: High-Dose Versus Standard-Dose Chemotherapy Frits S.A.M. van Dam, Willem Boogerd, Sanne B. Schagen, JNCI Journal of the National Cancer Institute	1998	768
Mutational Activation of the K-<i>ras</i>Oncogene Sjoerd Rodenhuis, Marcus L. van de Wetering, Wolter J. Mooi, New England Journal of Medicine GeneticsPathologyMolecular GeneticsCodon 12Tumor Biology	1987	536
Incidence and possible clinical significance of K-ras oncogene activation in adenocarcinoma of the human lung. Sjoerd Rodenhuis, Robbert J.C. Slebos, A J Boot, PubMed PathologyCancer BiologyTumor BiologyOncologyOligonucleotide Hybridization	1988	464
Phase II Study of ET-743 in Advanced Soft Tissue Sarcomas: A European Organisation for the Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group Trial Axel Le Cesne, Jean‐Yves Blay, Ian Judson, Journal of Clinical Oncology	2005	418
Imatinib mesylate (STI-571 Glivec®, Gleevec™) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target Jaap Verweij, A. van Oosterom, Jean‐Yves Blay, European Journal of Cancer OncologyGastrointestinal OncologyMolecular TargetMedicinePathology	2003	402
Clinical significance of ras oncogene activation in human lung cancer Sjoerd Rodenhuis, Robert J.C. Slebos Lung Cancer OncologyOncogenic AgentMedicinePathologyBronchial Neoplasm	1993	365
Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome Ian F. Faneyte, Jolanda Schrama, J.L. Peterse, British Journal of Cancer	2003	313
Magnetic Resonance Imaging Response Monitoring of Breast Cancer During Neoadjuvant Chemotherapy: Relevance of Breast Cancer Subtype Claudette E. Loo, Marieke E. Straver, Sjoerd Rodenhuis, Journal of Clinical Oncology	2011	299

Page 1